AR and nonpapillary renal cell carcinoma: Significantly, AR inhibition by shRNAs also increased pazopanib efficacy to suppress these two resistant cell lines (Fig. 1I), suggesting AR and it mediated VM at least partially contributed to ccRCC pazopanib resistant development.